Summary

The global HIV Post-Exposure Prophylaxis (PEP) Drugs market is projected to grow from US$ 185 million in 2025 to US$ 296 million by 2032, at a CAGR of 6.9% (2026-2032), driven by critical product segments and diverse end‑use applications.
HIV Post-Exposure Prophylaxis (PEP) Drugs refer to antiretroviral medicines administered after a potential HIV exposure to reduce the probability of establishing infection. The market primarily covers oral antiretroviral formulations used in standard PEP courses, including single-active-ingredient products and two-, three- and four-active-ingredient fixed-dose combinations. Current mainstream regimens are centered on integrase inhibitor-based three-drug therapy, with bictegravir or dolutegravir combined with a tenofovir-based nucleoside reverse transcriptase inhibitor backbone, while boosted protease inhibitor-based regimens remain alternatives for selected patients. Treatment is normally initiated as soon as possible following substantial occupational or nonoccupational exposure, ideally within 24 hours and no later than 72 hours, with a standard treatment duration of 28 days. The study focuses on commercial finished-dose antiretroviral products actually used for HIV PEP across occupational exposure, consensual sexual exposure, sexual assault exposure, injection drug use exposure and other nonoccupational blood or body-fluid exposure scenarios, covering branded originator products, licensed generics and other commercially supplied generic formulations.
Key Findings
Global HIV PEP drug consumption is estimated at approximately 43.7 million tablets in 2025 and 46.2 million tablets in 2026
Global PEP utilization corresponds to approximately 1.08 million treatment courses in 2025 and 1.16 million courses in 2026
North America and Europe together account for approximately 82% of 2026 market value, reflecting substantially higher realized drug prices
Integrase inhibitor-based three-drug regimens and fixed-dose combinations have become the mainstream product architecture for HIV PEP
Large-scale generic ARV procurement provides ample manufacturing capacity, while market value remains highly differentiated by region and pricing system
Market Trends
HIV Post-Exposure Prophylaxis (PEP) Drugs are moving toward simpler, better tolerated and lower-pill-burden regimens. Newer clinical recommendations favor second-generation integrase inhibitors, particularly bictegravir and dolutegravir, combined with two NRTIs, supporting increased use of three-active-ingredient fixed-dose combinations and simplified once-daily treatment. Bictegravir, emtricitabine and tenofovir alafenamide can provide a complete single-tablet regimen, while dolutegravir combined with TDF or TAF and FTC or 3TC remains a widely applicable architecture. The product mix is therefore gradually shifting away from older high-pill-burden combinations toward integrated fixed-dose products that improve adherence during the 28-day course. At the delivery level, PEP is also moving beyond specialist infectious-disease departments toward emergency care, sexual health services, occupational health programs and community-based access models, reflecting the critical importance of initiating treatment rapidly after exposure. Pediatric dispersible tablets, chewable tablets, oral suspensions and solutions remain a smaller but strategically important part of the product portfolio.
Market Dynamics
Drivers
Growth of HIV Post-Exposure Prophylaxis (PEP) Drugs is supported by broader recognition of PEP as an emergency HIV prevention intervention, improved awareness among exposed populations and healthcare professionals, and continued integration of PEP into national HIV prevention systems. Occupational sharps injuries, sexual exposure, sexual assault and injection-related exposure create recurring clinical demand, while policies emphasizing initiation within 72 hours increase the need for readily available starter packs and full 28-day courses. Expansion of emergency, sexual-health and community delivery networks further improves treatment accessibility.
Restraints
The market remains constrained by large differences in affordability and access between countries. High-income markets may use branded or higher-value newer-generation formulations, whereas public procurement programs in lower-income markets purchase highly commoditized generic ARVs at substantially lower prices. The Global Fund's 2026 reference price for a 30-tablet pack of dolutegravir, lamivudine and tenofovir is only US$2.80, illustrating the intense price compression in large-volume procurement markets. In addition, expanding PrEP use among populations with repeated HIV exposure can reduce recurring PEP demand, while stigma, delayed treatment-seeking and failure to present within the recommended 72-hour window continue to limit addressable utilization.
Opportunities
The most significant opportunities lie in improving rapid access and simplifying the treatment pathway. Wider availability through emergency departments, urgent-care centers, sexual health clinics, occupational health services and community-based channels can capture currently unmet PEP demand. Single-tablet three-active-ingredient fixed-dose combinations offer opportunities to reduce pill burden and support completion of the 28-day course, while pediatric formulations provide room for further product expansion. Emerging markets also offer considerable volume potential as national HIV programs strengthen post-exposure prevention services, although commercial models in these markets will remain more dependent on public procurement, licensing and cost-efficient generic manufacturing.
Challenges
The principal challenges are maintaining adherence throughout the full course, ensuring treatment can be initiated rapidly, managing drug interactions and comorbidities, and selecting appropriate alternatives where resistance or contraindications are present. Market measurement is also structurally difficult because most antiretroviral medicines used in PEP are shared with the much larger HIV treatment market rather than manufactured on dedicated PEP production lines. In the United States, current nPEP recommendations use established ARVs for the prevention setting rather than a separate portfolio of PEP-specific approved products. As a result, manufacturers and market participants must distinguish actual PEP consumption from treatment and PrEP volumes when assessing demand, inventory and revenue.
Industry Chain Analysis
The upstream segment of the HIV Post-Exposure Prophylaxis (PEP) Drugs industry consists primarily of pharmaceutical intermediates, antiretroviral APIs, excipients and pharmaceutical packaging materials. Major active ingredients include dolutegravir, bictegravir, tenofovir disoproxil fumarate, tenofovir alafenamide, emtricitabine, lamivudine, raltegravir and darunavir. Midstream activities comprise API synthesis, formulation development, fixed-dose combination development, regulatory filing, commercial-scale tablet manufacturing, pediatric formulation production, packaging and quality assurance. Vertically integrated generic manufacturers have a structural advantage in international procurement because control of both API and finished-dose formulation can improve cost competitiveness and supply reliability; Aurobindo, for example, reports integrated API and finished-dose ARV capabilities and supplies antiretroviral products to more than 125 countries.
Downstream distribution is fragmented by healthcare system. Products reach patients through emergency departments, urgent-care facilities, sexual health clinics, occupational health departments, sexual assault treatment services, public HIV programs, pharmacies and community-based delivery systems. Value creation differs substantially between segments: originator companies capture greater value through proprietary molecules, newer formulations and branded products, while generic manufacturers compete primarily through manufacturing scale, regulatory approvals, licensing, vertical integration and tender pricing. The very low international procurement price of mature ARVs means volume leadership does not necessarily translate into equivalent revenue leadership, making regional product mix and realized price critical determinants of market value.
Segment Insights
By Product Type, three-active-ingredient fixed-dose combinations represent the most strategically important product architecture because they can consolidate a complete three-drug regimen into one tablet. Products containing bictegravir, emtricitabine and tenofovir alafenamide illustrate the high-value single-tablet model, while tenofovir, lamivudine and dolutegravir combinations are especially important in cost-sensitive and large-scale procurement markets. Two-active-ingredient fixed-dose combinations remain important as NRTI backbones used together with a separate integrase inhibitor, while single-active-ingredient products provide flexibility for individualized regimens. Four-active-ingredient fixed-dose combinations are primarily associated with selected boosted protease inhibitor alternatives.
By Regimen Class, integrase inhibitor-based regimens are the mainstream clinical direction, while boosted protease inhibitor-based regimens serve mainly as alternatives. Within the NRTI Backbone Type segmentation, TDF-based products retain strong relevance in cost-sensitive procurement because of extensive generic availability, while TAF-based products are increasingly important in newer-generation regimens in higher-value markets. ABC-based and zidovudine-based products have more specific roles, including selected pediatric or alternative treatment situations. Oral tablets dominate Dosage Form, with dispersible tablets, chewable tablets, oral suspensions and oral solutions addressing pediatric and patients-specific administration requirements.
Downstream Market Opportunities
Application opportunities are centered on specific time-sensitive exposure scenarios rather than broad healthcare settings. Occupational Exposure PEP demand arises from needlestick injuries, contaminated sharps and mucosal blood exposure among healthcare and laboratory personnel. Consensual Sexual Exposure PEP is driven by substantial-risk sexual exposure such as condom failure or unprotected intercourse, while Sexual Assault Exposure PEP requires rapid access through emergency and specialist assault-care pathways. Injection Drug Use Exposure PEP addresses needle and injection-equipment sharing, and Other Nonoccupational Blood and Body Fluid Exposure PEP covers clinically significant blood or infectious-fluid contact with mucous membranes or nonintact skin. Expansion of rapid-access dispensing across these settings creates an opportunity to increase PEP uptake and improve completion rates without changing the underlying 28-day treatment standard.
Regional Insights
North America and Europe form the principal value centers for HIV Post-Exposure Prophylaxis (PEP) Drugs and together account for approximately 82% of the modeled 2026 market value, primarily because branded and newer-generation ARV formulations command significantly higher realized prices than internationally procured generics. Demand is supported by mature emergency-care, sexual-health and occupational-exposure systems. In England alone, sexual health services provided PEP to 8,463 people in 2024, up 4% from 2023, demonstrating continued utilization even in a market with expanding PrEP availability.
Latin America and Sub-Saharan Africa represent much larger volume opportunities relative to their value contribution, reflecting centralized public procurement and low generic ARV prices. Asia Pacific is structurally heterogeneous: Japan, South Korea and other developed markets favor higher-value branded or newer formulations, while China, India and Southeast Asia combine domestic generic manufacturing with expanding public-health access. Future regional growth will therefore depend less on global manufacturing capacity and more on awareness, rapid access, procurement funding and the integration of PEP into emergency and sexual-health services.
Competitive Landscape Analysis
The competitive landscape is characterized by a dual structure combining originator-led innovation with large-scale generic manufacturing. Gilead Sciences, ViiV Healthcare, Merck & Co. and Johnson & Johnson participate through important proprietary HIV molecules and branded formulations used within current or alternative PEP architectures, while Viatris, Cipla, Aurobindo Pharma, Hetero Labs, Macleods Pharmaceuticals, Laurus Labs and Emcure Pharmaceuticals provide significant generic and international-market supply capabilities. Aspen Pharmacare, Strides Pharma Science, Lupin, Micro Labs and Sun Pharmaceutical further broaden the generic manufacturing base, while Celltrion, Shanghai Desano Bio-Pharmaceutical and Zhejiang Huahai Pharmaceutical add regional and manufacturing capacity in Asia. Competitive differentiation is driven less by dedicated PEP manufacturing capacity than by ARV portfolio breadth, access to licensed molecules, regulatory approvals, manufacturing scale, API integration, fixed-dose combination capabilities and access to government or pooled procurement channels. Large generic suppliers have substantial volume advantages, while originator companies retain stronger exposure to higher-value markets and newer-generation formulations.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global HIV Post-Exposure Prophylaxis (PEP) Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Gilead Sciences, Inc.
ViiV Healthcare
Merck & Co., Inc.
Johnson & Johnson
Viatris Inc.
Cipla Limited
Aurobindo Pharma Limited
Hetero Labs Limited
Macleods Pharmaceuticals Limited
Laurus Labs Limited
Emcure Pharmaceuticals Limited
Aspen Pharmacare Holdings Limited
Strides Pharma Science Limited
Lupin Limited
Micro Labs Limited
Sun Pharmaceutical Industries Limited
Celltrion Inc.
Shanghai Desano Bio-Pharmaceutical Co., Ltd.
Zhejiang Huahai Pharmaceutical Co., Ltd.
Segment by Type
Single Active Ingredient Products
Two Active Ingredient Fixed Dose Combinations
Three Active Ingredient Fixed Dose Combinations
Four Active Ingredient Fixed Dose Combinations
Other
Segment by NRTI Backbone Type
Tenofovir Disoproxil Fumarate Based
Tenofovir Alafenamide Based
Abacavir Based
Zidovudine Based
Other
Segment by Application
Occupational Exposure PEP
Consensual Sexual Exposure PEP
Sexual Assault Exposure PEP
Injection Drug Use Exposure PEP
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the HIV Post-Exposure Prophylaxis (PEP) Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to HIV Post-Exposure Prophylaxis (PEP) Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Single Active Ingredient Products
1.2.3 Two Active Ingredient Fixed Dose Combinations
1.2.4 Three Active Ingredient Fixed Dose Combinations
1.2.5 Four Active Ingredient Fixed Dose Combinations
1.2.6 Other
1.3 Market Segmentation by NRTI Backbone Type
1.3.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size by NRTI Backbone Type, 2021 vs 2025 vs 2032
1.3.2 Tenofovir Disoproxil Fumarate Based
1.3.3 Tenofovir Alafenamide Based
1.3.4 Abacavir Based
1.3.5 Zidovudine Based
1.3.6 Other
1.4 Market Segmentation by Application
1.4.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size by Application, 2021 vs 2025 vs 2032
1.4.2 Occupational Exposure PEP
1.4.3 Consensual Sexual Exposure PEP
1.4.4 Sexual Assault Exposure PEP
1.4.5 Injection Drug Use Exposure PEP
1.4.6 Other
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue Estimates and Forecasts (2021-2032)
2.2 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Estimates and Forecasts (2021-2032)
2.4 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Single Active Ingredient Products: Market Share by Key Manufacturers
3.5.2 Two Active Ingredient Fixed Dose Combinations: Market Share by Key Manufacturers
3.5.3 Three Active Ingredient Fixed Dose Combinations: Market Share by Key Manufacturers
3.5.4 Four Active Ingredient Fixed Dose Combinations: Market Share by Key Manufacturers
3.5.5 Other: Market Share by Key Manufacturers
3.6 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Performance by Type
4.1.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume by Type (2021-2032)
4.1.2 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Performance by NRTI Backbone Type
4.2.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume by NRTI Backbone Type (2021-2032)
4.2.2 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by NRTI Backbone Type (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by NRTI Backbone Type (2021-2032)
4.3 Product Technology Differentiation
4.4 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.4.1 High-Growth Niches and Adoption Drivers
4.4.2 Profitability Hotspots and Cost Drivers
4.4.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Gilead Sciences, Inc.
11.1.1 Gilead Sciences, Inc. Corporation Information
11.1.2 Gilead Sciences, Inc. Business Overview
11.1.3 Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.1.4 Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Product in 2025
11.1.6 Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Application in 2025
11.1.7 Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Geographic Area in 2025
11.1.8 Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
11.1.9 Gilead Sciences, Inc. Recent Developments
11.2 ViiV Healthcare
11.2.1 ViiV Healthcare Corporation Information
11.2.2 ViiV Healthcare Business Overview
11.2.3 ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.2.4 ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Product in 2025
11.2.6 ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Application in 2025
11.2.7 ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Geographic Area in 2025
11.2.8 ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
11.2.9 ViiV Healthcare Recent Developments
11.3 Merck & Co., Inc.
11.3.1 Merck & Co., Inc. Corporation Information
11.3.2 Merck & Co., Inc. Business Overview
11.3.3 Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.3.4 Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Product in 2025
11.3.6 Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Application in 2025
11.3.7 Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Geographic Area in 2025
11.3.8 Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
11.3.9 Merck & Co., Inc. Recent Developments
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Corporation Information
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.4.4 Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Product in 2025
11.4.6 Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Application in 2025
11.4.7 Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Geographic Area in 2025
11.4.8 Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
11.4.9 Johnson & Johnson Recent Developments
11.5 Viatris Inc.
11.5.1 Viatris Inc. Corporation Information
11.5.2 Viatris Inc. Business Overview
11.5.3 Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.5.4 Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Product in 2025
11.5.6 Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Application in 2025
11.5.7 Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Geographic Area in 2025
11.5.8 Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
11.5.9 Viatris Inc. Recent Developments
11.6 Cipla Limited
11.6.1 Cipla Limited Corporation Information
11.6.2 Cipla Limited Business Overview
11.6.3 Cipla Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.6.4 Cipla Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 Cipla Limited Recent Developments
11.7 Aurobindo Pharma Limited
11.7.1 Aurobindo Pharma Limited Corporation Information
11.7.2 Aurobindo Pharma Limited Business Overview
11.7.3 Aurobindo Pharma Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.7.4 Aurobindo Pharma Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Aurobindo Pharma Limited Recent Developments
11.8 Hetero Labs Limited
11.8.1 Hetero Labs Limited Corporation Information
11.8.2 Hetero Labs Limited Business Overview
11.8.3 Hetero Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.8.4 Hetero Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Hetero Labs Limited Recent Developments
11.9 Macleods Pharmaceuticals Limited
11.9.1 Macleods Pharmaceuticals Limited Corporation Information
11.9.2 Macleods Pharmaceuticals Limited Business Overview
11.9.3 Macleods Pharmaceuticals Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.9.4 Macleods Pharmaceuticals Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Macleods Pharmaceuticals Limited Recent Developments
11.10 Laurus Labs Limited
11.10.1 Laurus Labs Limited Corporation Information
11.10.2 Laurus Labs Limited Business Overview
11.10.3 Laurus Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.10.4 Laurus Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Laurus Labs Limited Recent Developments
11.11 Emcure Pharmaceuticals Limited
11.11.1 Emcure Pharmaceuticals Limited Corporation Information
11.11.2 Emcure Pharmaceuticals Limited Business Overview
11.11.3 Emcure Pharmaceuticals Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.11.4 Emcure Pharmaceuticals Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Emcure Pharmaceuticals Limited Recent Developments
11.12 Aspen Pharmacare Holdings Limited
11.12.1 Aspen Pharmacare Holdings Limited Corporation Information
11.12.2 Aspen Pharmacare Holdings Limited Business Overview
11.12.3 Aspen Pharmacare Holdings Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.12.4 Aspen Pharmacare Holdings Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Aspen Pharmacare Holdings Limited Recent Developments
11.13 Strides Pharma Science Limited
11.13.1 Strides Pharma Science Limited Corporation Information
11.13.2 Strides Pharma Science Limited Business Overview
11.13.3 Strides Pharma Science Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.13.4 Strides Pharma Science Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Strides Pharma Science Limited Recent Developments
11.14 Lupin Limited
11.14.1 Lupin Limited Corporation Information
11.14.2 Lupin Limited Business Overview
11.14.3 Lupin Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.14.4 Lupin Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Lupin Limited Recent Developments
11.15 Micro Labs Limited
11.15.1 Micro Labs Limited Corporation Information
11.15.2 Micro Labs Limited Business Overview
11.15.3 Micro Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.15.4 Micro Labs Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Micro Labs Limited Recent Developments
11.16 Sun Pharmaceutical Industries Limited
11.16.1 Sun Pharmaceutical Industries Limited Corporation Information
11.16.2 Sun Pharmaceutical Industries Limited Business Overview
11.16.3 Sun Pharmaceutical Industries Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.16.4 Sun Pharmaceutical Industries Limited HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Sun Pharmaceutical Industries Limited Recent Developments
11.17 Celltrion Inc.
11.17.1 Celltrion Inc. Corporation Information
11.17.2 Celltrion Inc. Business Overview
11.17.3 Celltrion Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.17.4 Celltrion Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 Celltrion Inc. Recent Developments
11.18 Shanghai Desano Bio-Pharmaceutical Co., Ltd.
11.18.1 Shanghai Desano Bio-Pharmaceutical Co., Ltd. Corporation Information
11.18.2 Shanghai Desano Bio-Pharmaceutical Co., Ltd. Business Overview
11.18.3 Shanghai Desano Bio-Pharmaceutical Co., Ltd. HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.18.4 Shanghai Desano Bio-Pharmaceutical Co., Ltd. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Shanghai Desano Bio-Pharmaceutical Co., Ltd. Recent Developments
11.19 Zhejiang Huahai Pharmaceutical Co., Ltd.
11.19.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
11.19.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
11.19.3 Zhejiang Huahai Pharmaceutical Co., Ltd. HIV Post-Exposure Prophylaxis (PEP) Drugs Product Models, Descriptions and Specifications
11.19.4 Zhejiang Huahai Pharmaceutical Co., Ltd. HIV Post-Exposure Prophylaxis (PEP) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 HIV Post-Exposure Prophylaxis (PEP) Drugs Industry Chain
12.2 HIV Post-Exposure Prophylaxis (PEP) Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 HIV Post-Exposure Prophylaxis (PEP) Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 HIV Post-Exposure Prophylaxis (PEP) Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global HIV Post-Exposure Prophylaxis (PEP) Drugs Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Growth Rate by NRTI Backbone Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Region (US$ Million), 2021-2026
Table 6. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Region (US$ Million), 2027-2032
Table 7. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Tablets)
Table 8. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Region (K Tablets), 2021-2026
Table 9. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Region (K Tablets), 2027-2032
Table 10. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 11. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Manufacturers (K Tablets), 2021-2026
Table 12. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Share by Manufacturers (2021-2026)
Table 13. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Manufacturers (US$ Million), 2021-2026
Table 14. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue-Based Market Share by Manufacturers (2021-2026)
Table 15. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 16. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue, 2025
Table 17. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 18. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Average Selling Price (ASP) by Manufacturers (US$/Tablet), 2021-2026
Table 19. Key Manufacturers HIV Post-Exposure Prophylaxis (PEP) Drugs Manufacturing Base and Headquarters
Table 20. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Concentration Ratio (CR5)
Table 21. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 22. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 23. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume by Type (K Tablets), 2021-2026
Table 24. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume by Type (K Tablets), 2027-2032
Table 25. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Type (US$ Million), 2021-2026
Table 26. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Type (US$ Million), 2027-2032
Table 27. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume by NRTI Backbone Type (K Tablets), 2021-2026
Table 28. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume by NRTI Backbone Type (K Tablets), 2027-2032
Table 29. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by NRTI Backbone Type (US$ Million), 2021-2026
Table 30. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by NRTI Backbone Type (US$ Million), 2027-2032
Table 31. Technical Specifications by Key Product Type
Table 32. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Application (K Tablets), 2021-2026
Table 33. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales by Application (K Tablets), 2027-2032
Table 34. HIV Post-Exposure Prophylaxis (PEP) Drugs High-Growth Sectors Demand CAGR (2026-2032)
Table 35. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Application (US$ Million), 2021-2026
Table 36. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue by Application (US$ Million), 2027-2032
Table 37. Top Customers by Region
Table 38. Top Customers by Application
Table 39. North America HIV Post-Exposure Prophylaxis (PEP) Drugs Growth Accelerators and Market Barriers
Table 40. North America HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 41. North America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales (K Tablets) by Country (2021 vs 2025 vs 2032)
Table 42. Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Growth Accelerators and Market Barriers
Table 43. Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 44. Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Sales (K Tablets) by Country (2021 vs 2025 vs 2032)
Table 45. Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Sales (K Tablets) by Country (2021 vs 2025 vs 2032)
Table 47. Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Growth Accelerators and Market Barriers
Table 48. Southeast Asia HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Central and South America HIV Post-Exposure Prophylaxis (PEP) Drugs Investment Opportunities and Key Challenges
Table 50. Central and South America HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 51. Middle East and Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Investment Opportunities and Key Challenges
Table 52. Middle East and Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 53. Gilead Sciences, Inc. Corporation Information
Table 54. Gilead Sciences, Inc. Description and Major Businesses
Table 55. Gilead Sciences, Inc. Product Models, Descriptions and Specifications
Table 56. Gilead Sciences, Inc. Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 57. Gilead Sciences, Inc. Sales Value Proportion by Product in 2025
Table 58. Gilead Sciences, Inc. Sales Value Proportion by Application in 2025
Table 59. Gilead Sciences, Inc. Sales Value Proportion by Geographic Area in 2025
Table 60. Gilead Sciences, Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
Table 61. Gilead Sciences, Inc. Recent Developments
Table 62. ViiV Healthcare Corporation Information
Table 63. ViiV Healthcare Description and Major Businesses
Table 64. ViiV Healthcare Product Models, Descriptions and Specifications
Table 65. ViiV Healthcare Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 66. ViiV Healthcare Sales Value Proportion by Product in 2025
Table 67. ViiV Healthcare Sales Value Proportion by Application in 2025
Table 68. ViiV Healthcare Sales Value Proportion by Geographic Area in 2025
Table 69. ViiV Healthcare HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
Table 70. ViiV Healthcare Recent Developments
Table 71. Merck & Co., Inc. Corporation Information
Table 72. Merck & Co., Inc. Description and Major Businesses
Table 73. Merck & Co., Inc. Product Models, Descriptions and Specifications
Table 74. Merck & Co., Inc. Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 75. Merck & Co., Inc. Sales Value Proportion by Product in 2025
Table 76. Merck & Co., Inc. Sales Value Proportion by Application in 2025
Table 77. Merck & Co., Inc. Sales Value Proportion by Geographic Area in 2025
Table 78. Merck & Co., Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
Table 79. Merck & Co., Inc. Recent Developments
Table 80. Johnson & Johnson Corporation Information
Table 81. Johnson & Johnson Description and Major Businesses
Table 82. Johnson & Johnson Product Models, Descriptions and Specifications
Table 83. Johnson & Johnson Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 84. Johnson & Johnson Sales Value Proportion by Product in 2025
Table 85. Johnson & Johnson Sales Value Proportion by Application in 2025
Table 86. Johnson & Johnson Sales Value Proportion by Geographic Area in 2025
Table 87. Johnson & Johnson HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
Table 88. Johnson & Johnson Recent Developments
Table 89. Viatris Inc. Corporation Information
Table 90. Viatris Inc. Description and Major Businesses
Table 91. Viatris Inc. Product Models, Descriptions and Specifications
Table 92. Viatris Inc. Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 93. Viatris Inc. Sales Value Proportion by Product in 2025
Table 94. Viatris Inc. Sales Value Proportion by Application in 2025
Table 95. Viatris Inc. Sales Value Proportion by Geographic Area in 2025
Table 96. Viatris Inc. HIV Post-Exposure Prophylaxis (PEP) Drugs SWOT Analysis
Table 97. Viatris Inc. Recent Developments
Table 98. Cipla Limited Corporation Information
Table 99. Cipla Limited Description and Major Businesses
Table 100. Cipla Limited Product Models, Descriptions and Specifications
Table 101. Cipla Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 102. Cipla Limited Recent Developments
Table 103. Aurobindo Pharma Limited Corporation Information
Table 104. Aurobindo Pharma Limited Description and Major Businesses
Table 105. Aurobindo Pharma Limited Product Models, Descriptions and Specifications
Table 106. Aurobindo Pharma Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 107. Aurobindo Pharma Limited Recent Developments
Table 108. Hetero Labs Limited Corporation Information
Table 109. Hetero Labs Limited Description and Major Businesses
Table 110. Hetero Labs Limited Product Models, Descriptions and Specifications
Table 111. Hetero Labs Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 112. Hetero Labs Limited Recent Developments
Table 113. Macleods Pharmaceuticals Limited Corporation Information
Table 114. Macleods Pharmaceuticals Limited Description and Major Businesses
Table 115. Macleods Pharmaceuticals Limited Product Models, Descriptions and Specifications
Table 116. Macleods Pharmaceuticals Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 117. Macleods Pharmaceuticals Limited Recent Developments
Table 118. Laurus Labs Limited Corporation Information
Table 119. Laurus Labs Limited Description and Major Businesses
Table 120. Laurus Labs Limited Product Models, Descriptions and Specifications
Table 121. Laurus Labs Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 122. Laurus Labs Limited Recent Developments
Table 123. Emcure Pharmaceuticals Limited Corporation Information
Table 124. Emcure Pharmaceuticals Limited Description and Major Businesses
Table 125. Emcure Pharmaceuticals Limited Product Models, Descriptions and Specifications
Table 126. Emcure Pharmaceuticals Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 127. Emcure Pharmaceuticals Limited Recent Developments
Table 128. Aspen Pharmacare Holdings Limited Corporation Information
Table 129. Aspen Pharmacare Holdings Limited Description and Major Businesses
Table 130. Aspen Pharmacare Holdings Limited Product Models, Descriptions and Specifications
Table 131. Aspen Pharmacare Holdings Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 132. Aspen Pharmacare Holdings Limited Recent Developments
Table 133. Strides Pharma Science Limited Corporation Information
Table 134. Strides Pharma Science Limited Description and Major Businesses
Table 135. Strides Pharma Science Limited Product Models, Descriptions and Specifications
Table 136. Strides Pharma Science Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 137. Strides Pharma Science Limited Recent Developments
Table 138. Lupin Limited Corporation Information
Table 139. Lupin Limited Description and Major Businesses
Table 140. Lupin Limited Product Models, Descriptions and Specifications
Table 141. Lupin Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 142. Lupin Limited Recent Developments
Table 143. Micro Labs Limited Corporation Information
Table 144. Micro Labs Limited Description and Major Businesses
Table 145. Micro Labs Limited Product Models, Descriptions and Specifications
Table 146. Micro Labs Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 147. Micro Labs Limited Recent Developments
Table 148. Sun Pharmaceutical Industries Limited Corporation Information
Table 149. Sun Pharmaceutical Industries Limited Description and Major Businesses
Table 150. Sun Pharmaceutical Industries Limited Product Models, Descriptions and Specifications
Table 151. Sun Pharmaceutical Industries Limited Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 152. Sun Pharmaceutical Industries Limited Recent Developments
Table 153. Celltrion Inc. Corporation Information
Table 154. Celltrion Inc. Description and Major Businesses
Table 155. Celltrion Inc. Product Models, Descriptions and Specifications
Table 156. Celltrion Inc. Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 157. Celltrion Inc. Recent Developments
Table 158. Shanghai Desano Bio-Pharmaceutical Co., Ltd. Corporation Information
Table 159. Shanghai Desano Bio-Pharmaceutical Co., Ltd. Description and Major Businesses
Table 160. Shanghai Desano Bio-Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 161. Shanghai Desano Bio-Pharmaceutical Co., Ltd. Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 162. Shanghai Desano Bio-Pharmaceutical Co., Ltd. Recent Developments
Table 163. Zhejiang Huahai Pharmaceutical Co., Ltd. Corporation Information
Table 164. Zhejiang Huahai Pharmaceutical Co., Ltd. Description and Major Businesses
Table 165. Zhejiang Huahai Pharmaceutical Co., Ltd. Product Models, Descriptions and Specifications
Table 166. Zhejiang Huahai Pharmaceutical Co., Ltd. Sales (K Tablets), Revenue (US$ Million), Price (US$/Tablet) and Gross Margin (2021-2026)
Table 167. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
Table 168. Key Raw Materials Distribution
Table 169. Raw Materials Key Suppliers
Table 170. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 171. Milestones in Production Technology Evolution
Table 172. Distributors List
Table 173. Market Trends and Market Evolution
Table 174. Market Drivers and Opportunities
Table 175. Market Challenges, Risks, and Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources

List of Figures
Figure 1. HIV Post-Exposure Prophylaxis (PEP) Drugs Product Picture
Figure 2. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Single Active Ingredient Products Product Picture
Figure 4. Two Active Ingredient Fixed Dose Combinations Product Picture
Figure 5. Three Active Ingredient Fixed Dose Combinations Product Picture
Figure 6. Four Active Ingredient Fixed Dose Combinations Product Picture
Figure 7. Other Product Picture
Figure 8. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Growth Rate by NRTI Backbone Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 9. Tenofovir Disoproxil Fumarate Based Product Picture
Figure 10. Tenofovir Alafenamide Based Product Picture
Figure 11. Abacavir Based Product Picture
Figure 12. Zidovudine Based Product Picture
Figure 13. Other Product Picture
Figure 14. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Occupational Exposure PEP
Figure 16. Consensual Sexual Exposure PEP
Figure 17. Sexual Assault Exposure PEP
Figure 18. Injection Drug Use Exposure PEP
Figure 19. Other
Figure 20. HIV Post-Exposure Prophylaxis (PEP) Drugs Report Years Considered
Figure 21. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 23. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 24. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue-Based Market Share by Region (2021-2032)
Figure 25. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales (K Tablets), 2021-2032
Figure 26. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Tablets)
Figure 27. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Market Share by Region (2021-2032)
Figure 28. Top 5 and Top 10 Manufacturers HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume Market Share in 2025
Figure 29. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue-Based Market Share Ranking (2025)
Figure 30. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 31. Single Active Ingredient Products Revenue-Based Market Share by Manufacturer in 2025
Figure 32. Two Active Ingredient Fixed Dose Combinations Revenue-Based Market Share by Manufacturer in 2025
Figure 33. Three Active Ingredient Fixed Dose Combinations Revenue-Based Market Share by Manufacturer in 2025
Figure 34. Four Active Ingredient Fixed Dose Combinations Revenue-Based Market Share by Manufacturer in 2025
Figure 35. Other Revenue-Based Market Share by Manufacturer in 2025
Figure 36. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume-Based Market Share by Type (2021-2032)
Figure 37. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue-Based Market Share by Type (2021-2032)
Figure 38. Global HIV Post-Exposure Prophylaxis (PEP) Drugs ASP by Type (US$/Tablet), 2021-2032
Figure 39. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume-Based Market Share by NRTI Backbone Type (2021-2032)
Figure 40. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue-Based Market Share by NRTI Backbone Type (2021-2032)
Figure 41. Global HIV Post-Exposure Prophylaxis (PEP) Drugs ASP by NRTI Backbone Type (US$/Tablet), 2021-2032
Figure 42. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue-Based Market Share (2021-2032)
Figure 43. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Market Share by Application (2021-2032)
Figure 44. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue-Based Market Share by Application (2021-2032)
Figure 45. Global HIV Post-Exposure Prophylaxis (PEP) Drugs ASP by Application (US$/Tablet), 2021-2032
Figure 46. North America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales YoY (K Tablets), 2021-2032
Figure 47. North America HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue YoY (US$ Million), 2021-2032
Figure 48. North America Top 5 Manufacturers HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) in 2025
Figure 49. North America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume (K Tablets) by Application (2021-2032)
Figure 50. North America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) by Application (2021-2032)
Figure 51. US HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 52. Canada HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 53. Mexico HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 54. Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Sales YoY (K Tablets), 2021-2032
Figure 55. Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue YoY (US$ Million), 2021-2032
Figure 56. Europe Top 5 Manufacturers HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) in 2025
Figure 57. Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume (K Tablets) by Application (2021-2032)
Figure 58. Europe HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) by Application (2021-2032)
Figure 59. Germany HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 60. France HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 61. U.K. HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 62. Italy HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 63. Russia HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 64. Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Sales YoY (K Tablets), 2021-2032
Figure 65. Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue YoY (US$ Million), 2021-2032
Figure 66. Asia-Pacific Top 8 Manufacturers HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) in 2025
Figure 67. Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume (K Tablets) by Application (2021-2032)
Figure 68. Asia-Pacific HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) by Application (2021-2032)
Figure 69. Indonesia HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 70. Japan HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 71. South Korea HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 72. China Taiwan HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 73. India HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 74. Central and South America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales YoY (K Tablets), 2021-2032
Figure 75. Central and South America HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue YoY (US$ Million), 2021-2032
Figure 76. Central and South America Top 5 Manufacturers HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) in 2025
Figure 77. Central and South America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume (K Tablets) by Application (2021-2032)
Figure 78. Central and South America HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) by Application (2021-2032)
Figure 79. Brazil HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 80. Argentina HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 81. Middle East, and Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Sales YoY (K Tablets), 2021-2032
Figure 82. Middle East and Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue YoY (US$ Million), 2021-2032
Figure 83. Middle East and Africa Top 5 Manufacturers HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) in 2025
Figure 84. Middle East and Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Volume (K Tablets) by Application (2021-2032)
Figure 85. Middle East and Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Sales Revenue (US$ Million) by Application (2021-2032)
Figure 86. GCC Countries HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 87. Turkey HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 88. Egypt HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 89. South Africa HIV Post-Exposure Prophylaxis (PEP) Drugs Revenue (US$ Million), 2021-2032
Figure 90. HIV Post-Exposure Prophylaxis (PEP) Drugs Industry Chain Mapping
Figure 91. Regional HIV Post-Exposure Prophylaxis (PEP) Drugs Manufacturing Base Distribution (%)
Figure 92. Global HIV Post-Exposure Prophylaxis (PEP) Drugs Production Market Share by Region (2021-2032)
Figure 93. HIV Post-Exposure Prophylaxis (PEP) Drugs Production Process
Figure 94. Regional HIV Post-Exposure Prophylaxis (PEP) Drugs Production Cost Structure
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed